Enliven Therapeutics Financial Statements
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
40.98+0.35 (+0.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Enliven Therapeutics revenue and earnings
Enliven Therapeutics reported a net loss of $103.7 million, compared with a loss of $89.0 million a year earlier. Diluted earnings per share came in at -$1.83.
Summary generated from market data by MetaCap's automated system. Methodology
Enliven Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Operating Expenses | 119.66M | 104.55M | 83.53M | 38.79M | 51.44M | 41.70M | 24.12M |
| Research & Development | 85.86M | 80.78M | 64.57M | 31.02M | 38.44M | 32.15M | 19.01M |
| Operating Income | -119.66M | -104.55M | -83.53M | -38.79M | -51.44M | -41.70M | -24.12M |
| Other Income (Expense) | 15.96M | 15.53M | 11.95M | 1.13M | 58.00K | 338.00K | 653.00K |
| Pretax Income | — | — | — | 1.58M | -51.38M | — | — |
| Income Tax | 0 | 232.00K | 0 | 0 | — | — | — |
| Net Income | -103.69M | -89.02M | -71.58M | -37.66M | -51.38M | -41.36M | -23.46M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -1.83 | -1.89 | -2.01 | -12.05 | -2.37 | -3.53 | -33.40 |
| EPS (Diluted) | -1.83 | -1.89 | -2.01 | -12.05 | -2.37 | -3.53 | -33.40 |
| Shares Outstanding (Basic) | 56.66M | 47.07M | 35.55M | 3.12M | 21.66M | 13.92M | 702.46K |
| Shares Outstanding (Diluted) | 56.66M | 47.07M | 35.55M | 3.12M | 21.66M | 13.92M | 702.46K |
| EBITDA | -119.36M | -104.25M | -83.23M | -38.59M | -51.34M | -41.60M | -24.08M |
This table shows 7 annual periods of Enliven Therapeutics's income statement, from FY 2025 back to FY 2019, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow ELVN's reporting calendar. What is a income statement?